Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer.
about
Treatment pathways, resource use and costs in the management of small cell lung cancerOral treatment with etoposide in small cell lung cancer - dilemmas and solutions.G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity.Sensitivity analysis in economic evaluation: a review of published studies.Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
P2860
Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer.
description
1992 nî lūn-bûn
@nan
1992 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Potential cost savings of oral ...... ent of small cell lung cancer.
@ast
Potential cost savings of oral ...... ent of small cell lung cancer.
@en
Potential cost savings of oral ...... ent of small cell lung cancer.
@nl
type
label
Potential cost savings of oral ...... ent of small cell lung cancer.
@ast
Potential cost savings of oral ...... ent of small cell lung cancer.
@en
Potential cost savings of oral ...... ent of small cell lung cancer.
@nl
prefLabel
Potential cost savings of oral ...... ent of small cell lung cancer.
@ast
Potential cost savings of oral ...... ent of small cell lung cancer.
@en
Potential cost savings of oral ...... ent of small cell lung cancer.
@nl
P1433
P1476
Potential cost savings of oral ...... ent of small cell lung cancer.
@en
P2093
P304
P356
10.2165/00019053-199201040-00006
P577
1992-04-01T00:00:00Z
P6179
1045836734